~~<i id='F90A254E6C'><strike id='F90A254E6C'><tt id='F90A254E6C'><pre id='F90A254E6C'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：leisure time 2025-09-28 10:51:09 Page View：6575

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 5 important ways Henrietta Lacks changed medical science
Next article： Virginia high school admissions case could be legal follow

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

What the US credit downgrade means for the economy, your finances

1:44TheU.S.CapitolBuildingisshownonAug.1,2023inWashington.AnnaMoneymaker/GettyImagesAratingagencydow

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

Personalized medicine goes far beyond genetics

AdobeSincetheHumanGenomeProjectwascompletedin2003,mostpublicconsiderationsofpersonalizedmedicinehave